Celiac disease complications and cancer risk: how to read the numbers

Short answer

A 2025 European guideline calls the added cancer risk in non-refractory celiac disease “only slightly increased” and low in absolute terms1. Studies print a ratio next to an absolute rate, and the two read very differently: one Swedish study reports a ratio of 2.82 for lymphoproliferative malignancy beside an absolute rate of 70.3 per 100,000 person-years among people with celiac disease2, 3.

Published by Gluten Verdict · updated · 14 sources, each linked below

Reviewed by Mark Peter, Registered dietitian (RD), on

Binder-clipped paper packet with a yellow highlighter and reading glasses on a desk

Key points

  • A relative figure compares the risk in two groups; an absolute figure is a difference between groups or a rate11, 12. Trial-reporting guidelines recommend giving both4.
  • Coeliac UK lists small bowel cancer, a rare small bowel lymphoma (EATL), other non-Hodgkin lymphomas and Hodgkin lymphoma as slightly more likely in celiac disease, and says the majority of people with celiac disease do not develop them5, 6.
  • In a Swedish cohort study, the overall cancer hazard ratio in people with celiac disease was 1.11, but the increase was significant only in the first year after diagnosis (hazard ratio 2.47) and not afterwards (1.01)7.
  • Refractory celiac disease is rare: the 2025 European guideline puts it at approximately 0.3%–2% of adult patients, and says enteropathy-associated T-cell lymphoma (EATL) develops in up to half of those with its type II8, 9.
  • For people with non-refractory disease who are clinically stable and follow the diet, the 2025 European guideline does not recommend routine cancer surveillance beyond age- and risk-appropriate population screening10.

How do relative risk and absolute risk differ?

The studies below give two kinds of figure. Relative risk is the risk in one group divided by the risk in another group11; the studies below report hazard ratios as their relative figure. Absolute measures include the risk difference and the rate difference between two groups12; the studies below also print the absolute rate among the people with celiac disease.

A statistics tutorial in a medical journal notes that trial-reporting guidelines recommend giving both kinds4, and advises wariness of studies that report only relative measures, which can suggest a meaningful effect despite modest absolute differences in risk13. Its worked example is an intervention study with prostate cancer as the outcome, not celiac disease68.

The table puts the two side by side for four published Swedish studies. Each compares people whose celiac disease was found on an intestinal biopsy with matched reference individuals14, 15, 16, 17.

Four Swedish studies: the ratio and the absolute figure for the same outcome
Outcome and studyRelative figureAbsolute figure
Death from any cause (celiac disease diagnosed 1969 to 2017)14Hazard ratio 1.21189.7 vs 8.6 deaths per 1000 person-years; the study states an absolute difference of 1.2 per 1000 person-years18
Any cancer (47,241 people with celiac disease)15, 19Hazard ratio 1.1176.5 vs 5.7 cancers per 1000 person-years19
Lymphoproliferative malignancy (28,989 people with biopsy-verified celiac disease)16Hazard ratio 2.82270.3 per 100,000 person-years among people with celiac disease3
Small bowel adenocarcinoma (celiac disease diagnosed 1965 to 2017)17Hazard ratio 3.05, for the same count from 1 year after diagnosis20, 2129 patients (0.06%) vs 45 reference individuals (0.02%), counted from 1 year after diagnosis21; 1 extra case in every 2944 patients followed for 10 years22

Read the right-hand column for how often something happens and the middle column for how it compares. Neither column alone is the whole picture4.

Which complications does NIDDK list?

The US National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) lists long-term complications of celiac disease: accelerated osteoporosis or bone softening (osteomalacia), anemia, malnutrition, nervous system problems and problems related to the reproductive system. It lists adenocarcinoma of the small intestine, liver damage and non-Hodgkin lymphoma as rare complications23.

NIDDK also says that people with celiac disease who have no symptoms can still develop complications over time if they do not get treatment24, and that in untreated celiac disease, damage to the small intestine can lead to malabsorption and malnutrition25.

For children, NIDDK names slowed growth and short height, delayed puberty and damage to the enamel of permanent teeth among the effects of not absorbing nutrients during growth26. It adds that, depending on age at diagnosis, some, such as short height and tooth defects, may not improve27.

Our own guides cover the non-cancer complications one by one: bone density and osteoporosis, iron-deficiency anemia, liver enzymes, vitamin and mineral gaps and tooth enamel defects.

Which cancers are linked to celiac disease, and how rare are they?

Coeliac UK says research indicates that any increased cancer risk in celiac disease is much lower than previously believed28. It lists four cancers that are slightly more likely than in the general population: small bowel adenocarcinoma, a very rare small bowel lymphoma called enteropathy associated T cell lymphoma (EATL), other non-Hodgkin lymphomas, and Hodgkin lymphoma5.

The same page says lymphoma of the small bowel is rare in the UK, even in untreated celiac disease, and that the majority of people with celiac disease do not develop these cancers6. It describes EATL as affecting around one in a million people in the general population29, and says the likelihood stays very rare even with the slightly higher risk celiac disease brings30.

The 2025 European guideline names lymphoproliferative malignancies, small bowel adenocarcinoma and oesophageal cancer as cancers reported at increased relative risk, and adds that they remain rare events in absolute terms31.

What the lymphoma study found

In a Swedish study of biopsy-verified celiac disease, lymphoproliferative malignancy was associated with celiac disease (hazard ratio 2.82), and with small intestinal inflammation without villous atrophy (1.81), but not with latent celiac disease, meaning positive serology with a normal intestinal lining (0.97)2, 16. The study reports that celiac disease was associated with Hodgkin lymphoma and with both T-cell and B-cell non-Hodgkin lymphomas32.

Why the first year looks different

In that Swedish cohort, overall cancer risk was increased (hazard ratio 1.11), but the increase was significant only in the first year after diagnosis (2.47) and not afterwards (1.01), although the risks of hematologic, lymphoproliferative, hepatobiliary and pancreatic cancers persisted7. The authors conclude that the increase is confined to people diagnosed after age 40 and is primarily present within the first year of diagnosis33.

The European guideline reads the early excess as likely reflecting prolonged untreated disease before diagnosis rather than the effect of treated celiac disease34.

Coeliac UK also notes that there appears to be a lower risk of breast cancer and lung cancer in people with celiac disease35.

Does the gluten-free diet or gut healing change the risk?

Coeliac UK and the European guideline point the same way. Coeliac UK says a gluten-free diet lets the gut heal and reduces the already low risk, and that research suggests the risk falls with time from diagnosis to nearly the same as in the general population36. The European guideline says malignancy risk appears to decline over time with sustained adherence to a strict gluten-free diet and may approach that of the general population during long-term follow-up37.

Individual studies are narrower, and each has a limit worth knowing.

  • Swedish follow-up biopsies: among 7625 people who had one, 3308 (43%) had persistent villous atrophy. The lymphoproliferative cancer ratio against the general population (standardized incidence ratio) was 3.78 with persistent atrophy and 1.50 (95% confidence interval 0.77 to 2.62) with mucosal healing. The authors list a limitation: no data on dietary adherence38, 39.
  • Small bowel adenocarcinoma: mucosal healing was associated with a lower hazard ratio (0.18), but the authors say it failed to reach statistical significance40.
  • A multicentre cohort study: of 2211 patients, 694 had a follow-up biopsy and 157 of those had persistent villous atrophy. Complications and mortality were increased in the persistent-atrophy group, and poor adherence to the diet was among the predictors of persistent atrophy41, 42.

For how healing is measured and how long it takes, see our guides on the healing timeline and biopsy results and the Marsh scale.

What is refractory celiac disease, and how common is it?

NIDDK describes refractory celiac disease as a rare condition in which symptoms and damage to the small intestine continue or come back even on a strict gluten-free diet, and says it may lead to malnutrition or enteropathy-associated T-cell lymphoma43. The European guideline defines it as persistence or recurrence of symptoms and villous atrophy after at least 12 months on a strict diet, in the absence of other causes44.

Ongoing symptoms on the diet are common, and refractory disease is only one possible cause45, 46. NIDDK says symptoms continue or come back in about 20 percent of people despite the diet and may be caused by small amounts of gluten, other health problems or refractory disease45. Coeliac UK puts ongoing symptoms at around 1 in 3 people and says that most of the time gluten is still getting into the diet46.

How common refractory celiac disease is, by source
SourceWhat it says
European guideline (ESsCD, 2025)Approximately 0.3%–2% of adult patients, with most population-based studies suggesting 1% or less8. In referral and tertiary centres, 1%–4% of all celiac cases, which the guideline says likely reflects referral bias and overestimates community prevalence47
Coeliac UKBetween 4 in 100 to 3 in 1,000 people with coeliac disease, extremely rare under age 30 and mostly diagnosed over 50; it adds that the condition is thought to be over diagnosed48, 49
NIDDKCalls it a rare condition43

The guideline divides refractory disease into type I, the majority of cases, and type II, around 20%–30% of cases47. It reports a 5-year survival above 90% for type I against approximately 44%–58% for type II, which carries a significantly higher risk of progression to EATL50. In type II, the guideline says EATL develops in up to half of affected patients9. Coeliac UK likewise ties type 2 to a higher risk of complications including EATL51.

What do the mortality studies show, and what are their limits?

One Swedish study followed 49,829 people with celiac disease for a median of 12.5 years, during which 13.2% died52. Overall mortality was higher than in matched controls (9.7 vs 8.6 deaths per 1000 person-years)18. Deaths from cancer were 2.7 vs 2.2 per 1000 person-years, from cardiovascular disease 3.5 vs 3.4, and from respiratory disease 0.6 vs 0.553.

The gap was widest in the first year after diagnosis (15.3 vs 6.5 per 1000 person-years) and persisted beyond 10 years (10.5 vs 10.1)54. The authors call it an association with a small but statistically significant increased mortality risk55.

A 2024 meta-analysis of 25 studies found increased all-cause mortality (hazard ratio 1.16) and cancer mortality (1.21)56. It reports that mortality in celiac disease is increased, predominantly due to malignancies and particularly non-Hodgkin lymphoma, and that it has significantly decreased in recent decades57. Its authors list high heterogeneity and a lack of data for many countries as limitations58.

The studies cited here report death rates and hazard ratios compared with people without celiac disease, not life expectancy, and they describe groups, not any one person.

Which warning signs do the sources name?

Coeliac UK names persistent diarrhoea, stomach pain and unexplained weight loss as the main symptoms linked with EATL59. The European guideline lists persistent abdominal pain, unexplained weight loss, fevers and bowel obstruction as symptoms suggestive of lymphoma that people with refractory disease should be regularly assessed for60.

These are not a checklist for diagnosing yourself. Symptoms that continue on the diet may come from small amounts of gluten, other health problems or refractory disease45, and Coeliac UK says it is important not to guess the cause46. NIDDK advises talking with a doctor or registered dietitian, who can help find the cause61.

For persistent symptoms, the European guideline starts by verifying the original diagnosis and assessing gluten exposure62. Coeliac UK says the first step when non-responsive or refractory disease is suspected is usually an endoscopy with biopsy63.

What is follow-up care meant to catch?

NIDDK says a doctor may recommend regular follow-up visits to check that symptoms and health problems are improving on the diet, with antibody blood tests and, in some cases, additional biopsies to see whether the small intestine has healed64. It adds that doctors may recommend extra testing for people at risk of certain complications; a bone mineral density test to check for osteoporosis is its example65.

The European guideline describes follow-up as a chance to detect associated autoimmune disorders, address complications such as bone disease, and recognize warning signs that may suggest refractory disease or malignancy66. For a person with non-refractory disease who is clinically stable and follows the diet, it says follow-up should focus on dietary adherence, symptom review, nutritional status and alarm features, and that routine cancer surveillance beyond population screening is not recommended10.

It also says no studies show that a routine follow-up biopsy is absolutely necessary for every patient67.

This guide reports what the sources say. It is not advice for any one person: which tests, scans or biopsies make sense is a decision for the treating clinician.

Questions people ask

Does celiac disease raise the risk of cancer?

Sources report a small added risk of some cancers, mainly small bowel adenocarcinoma and lymphomas5, 31. The 2025 European guideline calls the risk in non-refractory disease only slightly increased and low in absolute terms1.

Does celiac disease shorten life expectancy?

The studies cited here report death rates rather than life expectancy. In a Swedish study, there were 9.7 vs 8.6 deaths per 1000 person-years, an absolute difference of 1.2 per 1000 person-years18, and a 2024 meta-analysis reports that mortality has significantly decreased in recent decades57.

How common is refractory celiac disease?

The European guideline gives approximately 0.3%–2% of adult patients8; Coeliac UK gives between 4 in 100 to 3 in 1,000 people with coeliac disease and says it is thought to be over diagnosed48, 49.

Is extra cancer screening recommended for people with celiac disease?

For clinically stable people with non-refractory disease who follow the diet, the European guideline says routine cancer surveillance beyond age- and risk-appropriate population screening is not recommended10.

More in Related conditions and complications

Sources